Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 33,061 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Not applicable Interventional Results available

Erythromycin in Parkinson's Disease

NCT02005029
View directory record Official record
Conditions
Parkinson's Disease, Levodopa
Interventions
Erythromycin, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

NCT00807937
View directory record Official record
Conditions
Anxiety Disorders
Interventions
AZD7325, Lorazepam, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
51
States / cities
Mesa, Arizona • Little Rock, Arkansas • Carson, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2010 · Synced Oct 17, 2026, 5:15 PM EDT
Active, not recruiting Phase 2 Interventional

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

NCT05230537
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Iptacopan (LNP023), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
22
States / cities
Fullerton, California • Huntington Beach, California • Rancho Cordova, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers

NCT01074372
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN727, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

NCT02116972
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
FX006 32 mg, Placebo, FX006 16 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
39
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 17, 2026, 5:15 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Putative Cognitive Enhancer VU319

NCT04051801
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Dose Escalation of VU319, Dose Escalation of Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

NCT01132612
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 3 Interventional

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

NCT01192867
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Antipshychotics (Standard of Care)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 2 Interventional

Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

NCT00036192
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
FK614
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
25 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
36
States / cities
Ozark, Alabama • Tucson, Arizona • Cypress, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2011 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism

NCT01039792
View directory record Official record
Conditions
Autistic Disorder
Interventions
Methyl B12, Placebo
Drug · Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 7 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 17, 2026, 5:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abatacept for SLE Arthritis (IM101-330)

NCT02429934
View directory record Official record
Conditions
Systemic Lupus Erythematosus Arthritis
Interventions
abatacept also known as Orencia also known as CTLA4-Ig, Placebo
Biological · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Not applicable Interventional Results available

Vitamin D Supplements for HIV-positive Patients on cART

NCT01295034
View directory record Official record
Conditions
HIV-associated Co-morbidities
Interventions
conventional vitamin D treatment, tiered/titrated vitamin D dosing
Dietary Supplement · Drug
Lead sponsor
Andrea Branch
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 17, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

NCT01480232
View directory record Official record
Conditions
Nicotine Dependence, Smoking Cessation
Interventions
EVP-6124, Placebo Capsule, NicoDerm Patch (Active), NRT Patch (Placebo), Brief Supportive and Behavioral Treatment
Drug · Behavioral
Lead sponsor
A. Eden Evins
Other
Eligibility
18 Years to 65 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 3 Interventional Results available

Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

NCT02106832
View directory record Official record
Conditions
Bronchiectasis
Interventions
Ciprofloxacin (BAYQ3939) dry powder for inhalation, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Peoria, Arizona • Fountain Valley, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 17, 2026, 5:15 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

NCT02768363
View directory record Official record
Conditions
Prostate Cancer
Interventions
aglatimagene besadenovec, placebo, valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Golden, Colorado • Chicago, Illinois • New Orleans, Louisiana + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

NCT02754687
View directory record Official record
Conditions
Healthy Men, Male Contraception
Interventions
Placebo, 11βmethyl nortestosterone dodecylcarbonate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

NCT05352893
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
750 mg Imsidolimab, 300 mg Imsidolimab, Placebo
Drug · Other
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 17, 2026, 5:15 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Not applicable Interventional Results available

Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk

NCT01156116
View directory record Official record
Conditions
Diabetes, Sleep Apnea
Interventions
CPAP mask, Placebo
Device · Drug
Lead sponsor
University of Chicago
Other
Eligibility
45 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 17, 2026, 5:15 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

NCT02655016
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
47
States / cities
Tempe, Arizona • Tucson, Arizona • San Francisco, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 17, 2026, 5:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of RSB11-HI Postbiotic Supplementation for Supporting Weight Management, Metabolic Wellness, and Quality of Life in Healthy Adults

NCT07788833
View directory record Official record
Conditions
Healthy Adults
Interventions
RSB11-HI Heat-Inactivated Postbiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Able Biolabs, LLC
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 1 Interventional

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

NCT03367533
View directory record Official record
Conditions
Depressive Disorder, Major, Post Traumatic Stress Disorder, Bipolar Disorder
Interventions
Ketamine, Perampanel, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 17, 2026, 5:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752
View directory record Official record
Conditions
Schizophrenia, Cognition, Psychosis
Interventions
Curcumin, Placebo
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 17, 2026, 5:15 PM EDT